このエントリーをはてなブックマークに追加
ID 16377
Eprint ID
16377
フルテキストURL
Thumnail 95_913.pdf 920 KB
タイトル(別表記)
STUDIES ON THE LONG-TERM SURVIVORS IN CHRONIC MYELOGENOUS LEUKFMIA AND THE CHEMOTHERAPY OF ITS BLASTIC PHASE Part 2 Studies on the Chemotherapy of Blastic Phase of CML
著者
北川 中行 岡山大学医学部第2内科教室
抄録
To improve the effect of chemotherapy of chronic myelogenous leukemic(CML) in blastic phase, the following clinical analysis were conducted. 1) The present study consisted of 53 adult patients with CML, who were registered to the 2nd Department of Medicine, Okayama University Hospital and diagnosed as blastic phase between from January 1970 to March 1980. There were 29 males and 24 females, and age ranged from 15 to 77 years (median: 41). 2) These 53 patients were divided into 4 groups. i) Group I-A (5 cases) was diagnosed as blastic crisis(BC) with hiatus leukemicus(HL) and initially treated with multicombination chemotherapy such as NCD, DMP or NCDP regimens (N: Neocarzinostatin, C: Cytosine arabinoside, D: Daunorubicin, M; 6-Mercaptopurine, P: Prednisolone). ii) Group I-B (16 cases) was diagnosed as BC with HL and initially treated with VP or VPM regimens (V: Vincristine, P: Prednisolone, M: 6-Mercaptopurine). iii) Group II-A (11 cases) was early diagnosed as BC without HL according to our established criteria, and initially treated with multicombination chemotherapy such as NCMP, DCMP, NDMP, NCDP or NCDVP. and, iv) Group II-B (21 cases) was early diagnosed as BC without HL and initially treated with VP, MP, or VPM. 3) Complete remission(CR) rate of each group was 20.0% in Group I-A, 56.2% in Group I-B, 27.3% in Group II-A and 47.6% in Group II-B. 4) Median survival and its surviving ranges after BC of each group were 3.6 months (1.8-4.5), 6.7 (1.0-24.2), 6.0 (2.6-22.8) and 13.0 (4.1-43.5). Median survival of CR-responders was 3.6, 10.0, 8.7 and 17.0 months, respectively. 5) The rate of one-year survivors of each group was 0%, 31.3% 9.1% and 52.4%. 6) In conclusion, the most ideal approach to prolongation of the survival period of CML patients after entering BC is i) to diagnose BC as early and accurate as possible, and ii) to treat these patients initially with rather mild regimens such as VP or VPM, instead of aggressive regimens with multicombination drugs.
キーワード
慢性骨髄性白血病
急性転化
早期診断・早期治療
V(M)P療法
発行日
1983-10-30
出版物タイトル
岡山医学会雑誌
出版物タイトル(別表記)
Journal of Okayama Medical Association
95巻
9-10号
出版者
岡山医学会
出版者(別表記)
Okayama Medical Association
開始ページ
913
終了ページ
927
ISSN
0030-1558
NCID
AN00032489
資料タイプ
学術雑誌論文
オフィシャル URL
https://www.jstage.jst.go.jp/article/joma1947/95/9-10/95_9-10_913/_article/-char/ja/
関連URL
http://www.okayama-u.ac.jp/user/oma/index.html
言語
Japanese
著作権者
岡山医学会
論文のバージョン
publisher
査読
有り
Eprints Journal Name
joma